Gregory Franz, MD, MPH

Pembrolizumab in adjuvant NSCLC therapy can trigger central adrenal insufficiency with vague fatigue, nausea, and hyponatremia.

This case highlights the importance of recognizing ICPI-AKI, implementing effective therapeutic interventions, and understanding the clinical context to prevent irreversible renal damage.